Oruka Therapeutics (ORKA) vs. Its Rivals Financial Contrast

Oruka Therapeutics (NASDAQ:ORKA) is one of 39 public companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Oruka Therapeutics to similar businesses based on the strength of its risk, institutional ownership, earnings, analyst recommendations, valuation, profitability and dividends.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-79.39%	-76.69%
Oruka Therapeutics Competitors	-2,067.72%	-46.71%	-27.39%

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Oruka Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-3.84
Oruka Therapeutics Competitors	$553.23 million	$6.13 million	-106.57

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Oruka Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.28, suggesting that their average stock price is 28% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Oruka Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	876	818	1361	24	2.17

Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 79.56%. As a group, “Diagnostic substances” companies have a potential upside of 51.08%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than its peers.

Summary

Oruka Therapeutics beats its peers on 8 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.